R&D strategy and stock price volatility in the biotechnology industry

Review of Accounting and Finance

Volumn 5, Issue 1, 2006, Pages 59-71

  Xu, Bixia ^a  

^a WILFRID LAURIER UNIVERSITY   (Canada)

Author keywords

Biotechnology; Economic fluctuations; Investments; Research and development; Share prices

Indexed keywords

EID: 84992975017     PISSN: 14757702     EISSN: 17587700     Source Type: Journal    
DOI: 10.1108/14757700610646943     Document Type: Article

References (33)

1. Allen, E. and Rachim, V. (1996), “Dividend policy and stock price volatility: australian evidence”, Applied Financial Economics, Vol. 6, pp. 175-88.
2. Alvarez, T. (2001), “Heavy use of stock options linked to stock price volatility”, Workspan, Vol. 44, pp. 13-15.
3. Baskin, J. (1989), “Dividend policy and the volatility of common stocks”, Journal of Portfolio Management, Vol. 15, pp. 19-25.
4. Ben-Zion, U. and Shalit, S. (1975), “Size, leverage, and dividend record as determinants of equity risk”, The Journal of Finance, Vol. 30, pp. 1015-26.
5. Cumby, J. and Conrod, J. (2001), “Non-financial performance measures in the Canadian biotechnology industry”, Journal of Intellectual Capital, Vol. 2, pp. 261-72.
6. DiMasi, A. (1991), “Cost of innovation in the pharmaceutical industry”, Journal of Health Economics, Vol. 10, pp. 107-42.
7. DiMasi, A. (1995), “Success rate for new drug entering clinical testing in the United States”, Clinical Pharmacology and Therapeutics, Vol. 58, pp. 1-14.
8. Dasgupta, P. and Stiglitz, J. (1980), “Uncertainty, industrial structure and the speed of R&D”, Bell Journal of Economics, Vol. 11, pp. 1-28.
9. Emst, H. and Soll, J. (2003), “An integrated portfolio approach to support market-oriented R&D planning”, International Journal of Technology Management, Vol. 26, pp. 540-6.
10. Ewing, T. (1999), “Small-stock focus: Nasdaq stock's price ricochet is for the books”, Wall Street Journal, February 17, pp. C1.
11. Fama, F. and French, K. (1992), “The cross sections of expected stock returns”, Journal of Finance, June, pp. 427-65.
12. Frank, R. (2003), “New estimates of drug development costs”, Journal of Health Economics, Vol. 22, pp. 325-30.
13. Hemantha, H. and Chan, P. (1999), “Economic analysis of R&D projects: an options approach”, The Engineering Economist, Vol. 44, pp. 1-35.
14. Hoskisson, E. and Hill, A. (1990), “Antecedents and performance of outcomes of diversification: a review and critique of theoretical perspectives”, Journal of Management, Vol. 16, pp. 461-509.
15. Hotchkiss, E. and Strickland, D. (2003), “Does shareholder composition matter? Evidence from the market reaction to corporate earnings announcements”, The Journal of Finance, Vol. 58, pp. 1469-99.
16. Hull, J. (2000), Options, Futures, and Other Derivatives, 4th ed., Prentice Hall, Englewood Cliffs, NJ.
17. Jacobs, J. (2001), “Creating a successful biotech firm”, Business Times, August 2, pp. 5.
18. Kellogg, D. and Charnes, J. (2000), “Real-option valuation for a biotechnology company”, Financial Analysts Journal, May/June, pp. 76-84.
19. Markowitz, H. (1952), “Portfolio selection”, Journal of Finance, Vol. 25, pp. 71-79.
20. Ramanujam, V. and Variadarajan, P. (1989), “Research on corporate diversification: a synthesis”, Strategic Management Journal, Vol. 10, pp. 523-52.
21. Parkinson, G. (1987), “How to succeed in biobusiness”, Chemical Week, Vol. 141, pp. 46-48.
22. Ringuest, J., Graves, S. and Case, R. (1999), “Formulating R&D portfolios that account for risk”, Research Technology Management, Vol. 42, pp. 40-44.
23. Robbins-Roth, C. (2000), From Alchemy to IPO: The Business of Biotechnology, Perseus Publishing.
24. Rumelt, P. (1974), Strategy, Structure and Economic Performance, Harvard University Press, Cambridge, MA.
25. Sadorsky, P. (2003), “The macroeconomic determinants of technology stock price volatility”, Review of Financial Economics, Vol. 12, pp. 191-205.
26. Sharpe, W. (1964), “Capital asset prices: a theory of market equilibrium under conditions of risk”, The Journal of Finance, September, pp. 425-42.
27. Shi, C. (2003), “On the trade-off between the future benefits and riskiness of R&D: a bondholders” perspective”, Journal of Accounting and Economics, Vol. 35, pp. 227-54.
28. Stern, I. and Henderson, A. (2004), “Within-business diversification in technology-intensive industry”, Strategic Management Journal, Vol. 25, pp. 487-505.
29. Walter, K. (1997), “Building effective R&D capabilities abroad”, Harvard Business Review, Vol. 75, pp. 61-71.
30. Weintraub, A. (2004), “Repairing the engines of life; can research into stem cells and other advanced techniques heal ailing hearts and brains?” Business Week, Vol. 24 May, pp. 98-106.
31. Xu, B., Magnan, M. and Andre, P. (2004), “The quality of the drug portfolio and the value relevance of R&D expenditures in biotech firms”, working paper, Wilfrid Laurier University, Waterloo, Concordia University, Montreal and University of Edinburgh, Edinburgh.
32. Larcker, D. (2003), Discussion of “are executive stock price options associated with future earnings?”, Journal of Accounting and Economics, Vol. 36, pp. 91-103.
33. Hayn, C. (1995), “The information content of losses”, Journal of Accounting and Economics, Vol. 20, pp. 125-53.